ALXO ALX ONCOLOGY HOLDINGS INC

ALXO financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1810182 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Aug 6, 2026 Data checked: Oct 21, 2026
Showing 3 of 8 annual and 0 of 30 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$18.00M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
650-466-7125
EIN
850642577
Headquarters
SOUTH SAN FRANCISCO, CA, 94080
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Jun 30, 2026
Financials
Revenue
-
Net Income
$-80.89M
Total Assets
$160.82M
Total Equity
$136.19M
Total Debt
$9.71M
Free Cash Flow
$-70.95M
Ratios
Return on Equity
-59.4%
Return on Assets
-50.3%
Current Ratio
9.71x
Debt / Equity
0.07x
FCF / Assets
-44.1%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Fiscal 2025 results for ALX ONCOLOGY HOLDINGS INC included net loss of $101.69M. The company reported diluted EPS of -$1.90, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 53.66M; this is the reported share base over which the company’s diluted per-share earnings were spread. Compared with 52.17M diluted shares in fiscal 2024, the current 53.66M base was 2.8% higher. Total assets stood at $59.05M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

The reported operating result was an operating loss of $104.02M, reflecting costs that exceeded gross profit. The bottom-line result was a net loss of $101.69M after operating, financing, tax, and other recognized items. Negative EBITDA totaled $103.32M, confirming that the earnings deficit remained before depreciation and amortization. The company reported a pretax loss of $101.69M, before the effect of income taxes. The company recognized $0.00 of income tax for the period, completing the transition from pretax income to net income. The net loss equaled 391.4% of period-end equity, showing the deficit relative to book capital. The net loss equaled 172.2% of period-end assets, showing the deficit relative to the asset base. The bottom-line deficit decreased from $134.85M in fiscal 2024 to $101.69M.

Liquidity and Capital Structure

Total assets were $59.05M, supported by $33.06M of liabilities and $25.98M of shareholder equity. Current assets were $50.73M against $24.55M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 2.07x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Cash and equivalents totaled $16.37M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 66.7%, excluding receivables and other current assets. Borrowings totaled $9.75M, adding a fixed financing obligation alongside the company’s equity capital. Debt equaled 0.38x of book equity, describing the relative scale of borrowing and shareholder capital. The debt-to-assets relationship was 16.5%, comparing borrowing with the total asset balance. Equity equaled 44.0% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 56.0%, complementing the separate equity-based view of the company’s capital structure. Measured against total assets, cash and equivalents represented 27.7%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $147.78M in fiscal 2024, the current asset base moved 60.0% and finished lower. Against $113.62M of equity in fiscal 2024, the current book-equity balance moved 77.1% and ended lower. Compared with $17.57M in fiscal 2024, the current cash balance moved 6.8% and finished lower.

Cash Flow and Earnings Quality

Operating activities used $84.14M of cash, resulting in an operating cash outflow for the year. Capital expenditures used $212.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. Negative free cash flow was $84.35M, leaving a cash deficit after capital spending and reducing financial flexibility. The free-cash-flow deficit equaled 142.9% of total assets, placing the cash shortfall against the company’s resource base. Cash absorbed by operations decreased from $121.91M in fiscal 2024 to $84.14M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for ALX ONCOLOGY HOLDINGS INC
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
OPERATING EXPENSES
R&D Expense $77.00M $116.37M $141.80M
SG&A Expense $23.85M $26.09M $28.48M
Operating Income $-104.02M $-142.47M $-170.28M
NON-OPERATING INCOME / EXPENSE
Interest Expense $1.60M $1.73M $1.57M
Interest Income $3.96M $9.37M $10.65M
Other Income/Expense $-36.00K $-20.00K $389.00K
Pretax Income $-101.70M $-134.85M $-160.81M
Income Tax $0 $0 $0
Net Income $-101.70M $-134.85M $-160.81M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-1.90 $-2.58 $-3.74
Diluted Shares 53.66M 52.17M 42.99M
EBITDA $-103.32M $-141.57M $-169.48M
Depreciation & Amortization $700.00K $900.00K $800.00K
Balance Sheet
ASSETS
Cash & Equivalents $16.37M $17.57M $22.41M
Short-term Investments $28.42M $110.19M $160.33M
Other Current Assets $20.00K $27.00K $439.00K
Current Assets $50.73M $134.35M $188.66M
PP&E (Net) $1.20M $2.91M $3.59M
Other Noncurrent Assets $3.63M $6.99M $14.89M
Noncurrent Assets $8.32M $13.42M $53.89M
Total Assets $59.05M $147.78M $242.55M
LIABILITIES
Accounts Payable $4.91M $4.50M $8.59M
Short-term Debt $5.22M $435.00K $0
Other Current Liabilities $0 $149.00K $543.00K
Current Liabilities $24.55M $18.50M $36.00M
Long-term Debt $4.53M $9.47M $9.64M
Other Noncurrent Liabilities $3.98M $6.19M $7.20M
Noncurrent Liabilities $8.51M $15.66M $16.84M
Total Liabilities $33.07M $34.16M $52.84M
EQUITY
Common Stock $54.00K $53.00K $50.00K
Additional Paid-in Capital $748.72M $734.41M $675.68M
Retained Earnings $-722.82M $-621.12M $-486.27M
Accumulated OCI $28.00K $275.00K $256.00K
Total Equity $25.98M $113.62M $189.71M
Total Liabilities & Equity $59.05M $147.78M $242.55M
SUPPLEMENTAL
Total Debt $9.75M $9.90M $9.64M
Shares Outstanding 54.39M 53.05M 49.95M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-84.14M $-121.91M $-130.36M
Capital Expenditures $212.00K $447.00K $1.27M
Cash from Investing $82.59M $86.26M $44.66M
Cash from Financing $362.00K $30.82M $59.29M
Free Cash Flow $-84.35M $-122.36M $-131.64M
Beginning Cash (CFS) $17.63M $22.47M $48.89M
Net Change in Cash $-1.19M $-4.84M $-26.42M
Effect of FX on Cash - - -
Calculated Ending Cash $16.44M $17.63M $22.47M
Cash per BS $16.37M $17.57M $22.41M
Cash scope difference (CFS − BS) $66.00K $66.00K $66.00K
Cash per CFS $16.44M $17.63M $22.47M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is ALX ONCOLOGY HOLDINGS INC profitable?

No. ALX ONCOLOGY HOLDINGS INC reported $-80.89M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

What is ALX ONCOLOGY HOLDINGS INC's debt level?

ALX ONCOLOGY HOLDINGS INC carries $9.71M in total debt as of trailing twelve months. Total shareholders' equity stands at $136.19M.

Does ALX ONCOLOGY HOLDINGS INC generate free cash flow?

No. Free cash flow was $-70.95M for trailing twelve months. Operating cash flow was $-70.78M.